Cencora Deep-Dive Value Investment Analysis

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it enlarging a slice of an existing pie, or creating an entirely new market?5/10

  A

  The ceiling is very high, but this is about "enlarging a slice of an existing pie," not creating a brand-new market — and that is what makes Cencora's growth "steady and thick" rather than "steep."

  First, how big is the pie itself. Cencora is in U.S. and international pharmaceutical distribution, with FY2025 revenue of about $321.3B (i.e., $321.3B), and TTM revenue already at $328.7B. The pool it operates in is still growing: CMS projects U.S. total health spending will grow at an average annual rate of 5.8% over 2024–2033, faster than GDP, and 2024 prescription drug spending rose 7.9% year over year to $467B; IQVIA estimates U.S. net drug spending had risen to $606B in 2025 and projects an additional roughly $200B by 2030 versus 2025. In other words, underlying demand is structurally driven by population aging, innovative drugs, oncology, immunology, obesity (GLP-1), and specialty medicines, and the ceiling is out of sight on a ten-year horizon.

  But here we must apply an honest discount to any Baillie Gifford-style "blue-sky imagination": Cencora is not opening up virgin territory; it is grabbing existing share in a mature market that has already been fully carved up. In its materials on pharmaceutical distribution competition, the FTC states clearly that after long-term consolidation the United States is left with only three large national wholesalers, and Cencora is one of them. In other words, its growth ceiling is jointly framed by "total U.S. drug distribution volume × the share it can defend/capture × the extra service gross margin it can earn per order," not by pioneering an unprecedented category to scale TAM exponentially. The real "increment" it is generating has two parts: one is rising with the broader market (volume growth plus drug price/mix), and the other is extending itself from a "box-moving distributor" toward a "service platform embedded in specialty care" — OneOncology (community oncology), RCA, EyeSouth retina, and PharmaLex all point this way, aiming to capture a higher-margin wallet share from the same set of customers.

  So the conclusion: this is a good business with a high enough ceiling that can feed on health-spending growth for the long run, but its growth narrative is about "making its own slice thicker and taller within a huge existing pie," not "creating a brand-new market." By Baillie Gifford's LTGG "five-fold in ten years" yardstick, the 5%–6% growth of the pure-distribution market is far from enough; whether it can offer excess upside depends almost entirely on how much the "climbing" curve of the specialty-service platform can deliver — and that part is still in the M&A-integration and proof phase today.

  Jun 11, 2026
• QCan its revenue at least double over the next five years? Is growth driven mainly by volume, price, or new businesses?4/10

  A

  Doubling within five years is almost impossible — under the current structure, five-year revenue most likely grows only 30%–40%, and growth relies mainly on "volume" (prescription volume plus drug price/mix) rather than "price" (weak pricing power), with new-business M&A only a marginal accelerator.

  First, calibrate expectations with historical growth. Cencora's revenue grew from $167.9B in 2018 to $321.3B in FY2025, roughly 1.9x over seven years, a compound growth rate of about 9.7%; but a considerable part of that came from high-revenue, low-margin categories like GLP-1 inflating the headline scale. The recent real pace is more telling: FY2026 Q2 total revenue was $78.4B, up only 3.8% year over year, of which U.S. revenue was about $68.8B (up 2.9%) and international revenue about $7.6B (up 13.0%). Putting these together: the U.S. book, which is the bulk (about 88%), runs only in the low single digits, and the international book, though fast, is small in base. To double total revenue in five years would require a compound growth rate of about 14.9%, five times the current U.S. core growth rate — which is unrealistic in a mature existing market carved up by three oligopolists.

  Next, break down the three drivers and characterize each honestly:

  • Volume: this is the main engine. Prescription volume grows steadily with aging and the ramp of innovative drugs; specialty drugs, sales of specialty products to health systems and physician practices, and GLP-1-related products are the explicit sources of FY2026 Q2 U.S. growth. This part is real and sustainable, but its natural pace is the 5%–6% magnitude of the overall health-spending market.
  • Price: very weak. This business does not make money by "raising prices directly"; the company itself noted in FY2026 Q2 that higher GLP-1 volumes actually drag down gross margin, and it relies on mix, contract terms, and efficiency to partly pass through costs rather than consumer-goods-style price hikes. So "price" is not a source of a revenue doubling.
  • New businesses: accelerators, not disruptors. Acquisitions like OneOncology (enterprise value about $7.4B, Cencora cash consideration about $5.0B), RCA, and PharmaLex do consolidate to add revenue and higher margins, but relative to the $320B scale, revenue of several billion per deal is only a single-digit-percentage contribution, and it must be sustained by continuous M&A — not an organic, exponential second curve.

  A counterforce that must be faced squarely: in FY2026 Q2 Cencora explicitly noted that volumes at a large mail-order customer declined, and in 2025 it also lost an oncology customer and a grocery customer — losing large customer contracts directly offsets part of the growth. This is also why the revenue-doubling narrative is especially fragile in this business.

  Conclusion: doubling in five years is not this company's realistic path; a more reasonable baseline is steady mid-single-digit growth that is "volume-led, with price contributing almost nothing and M&A providing marginal acceleration." It is a compounding machine that grinds steadily on massive throughput, not a growth stock that rewrites its valuation via revenue explosions — which does not fit Baillie Gifford LTGG's hard "revenue doubles in five years" threshold.

  Jun 11, 2026
• QFive years out, what will take the baton as the next growth engine? Does this "second curve" exist today?4/10

  A

  The second curve does indeed already exist today, and it is tangible — it is the extension "from distribution logistics toward a high-margin specialty-care and service platform"; but it is more like a "thickened, upgraded version" of the core business than a brand-new growth pole that can independently take the company to five-fold in ten years.

  The specific vehicles of this curve are clear: OneOncology (community oncology care platform), RCA (regulatory-compliance services), the EyeSouth retina/ophthalmology platform, and PharmaLex (pharmaceutical regulatory affairs). The logic is to migrate itself from "a distributor earning a thin spread per box" toward "embedding into oncology, ophthalmology, and other specialty-care chains and collecting higher-margin service fees." This is not a slide-deck concept; the marginal effect is already visible in the financials: in FY2026 Q2 the company explicitly said OneOncology lifted the U.S. business's gross margin and operating profit, and international revenue up 13.0% year over year also outpaced the U.S. core's +2.9% (see Q2 FY2026 results). Directionally, this is precisely the engine with which the company is trying to pry gross margin up from "razor-thin" — FY2025 gross profit had risen from $8.96B in FY2023 to $11.48B, showing that growth relies increasingly on category/service mix rather than simply scaling throughput.

  But three honest reservations must be made against Baillie Gifford's standard that "the second curve must be able to take the baton as the main engine":

  First, the scale is mismatched. OneOncology's cash consideration was about $5.0B, enterprise value about $7.4B; placed within a $321.3B revenue body, the specialty platform can contribute only a single-digit percentage in the near term, far too little to "take the baton" as the company's main growth. It thickens profit and increases stickiness for the main curve rather than launching a new principal axis capable of independently holding up the valuation.

  Second, it is "bought" rather than "grown." This curve depends heavily on continuous M&A to feed it, and M&A inherently brings amortization, impairment, and leverage — the company had $837M of asset impairment in FY2025, and by the first half of FY2026 net interest expense jumped sharply year over year due to OneOncology and earlier acquisition financing. The report therefore holds management and capital allocation at 3.5/5 and stresses that "whether the specialty platform can truly lift long-term quality is still in the delivery phase." A bought second curve takes longer to prove and carries lower certainty.

  Third, it thickens quality but does not necessarily rewrite the growth rate. Specialty services can raise gross margin and increase stickiness, but as noted above, doubling total revenue in five years remains unrealistic — so this curve's value lies in "turning thin profit into thicker profit and improving cash-flow quality," not in "re-accelerating revenue."

  Conclusion: the second curve exists, points the right way, and has early delivery; it is the most imaginative part of this bull case. But it is essentially an "upward extension" of the core distribution moat, and its scale and certainty are still not enough to support five-fold in ten years on their own. It can make Cencora a "higher-quality" business, but it can hardly turn it into a "faster" growth stock — which is precisely the core reason the report assigns "Watch" rather than "Buy" and demands continued proof that M&A is creating per-share value.

  Jun 11, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?5/10

  A

  The core competitive advantage is an infrastructure moat that is a trinity of "scale cost + switching cost + license/compliance"; over the next three to five years, the pure-distribution layer of the moat is broadly stable (neither widening nor visibly narrowing), while the "specialty-service" layer stacked on top is slowly widening. Overall it is fairly wide and solid, but it is not the top-tier network-type moat that self-accelerates and deepens as it rolls.

  The four sources of the moat, characterized one by one:

  • Scale and cost (strong): U.S. national pharmaceutical distribution is already highly concentrated; the FTC explicitly describes the industry, after consolidation, as a "three national wholesalers" structure, and Cencora is one of them. Scale brings unit-cost advantages in procurement bargaining, warehousing, IT, route density, and operational synergy, and credit-rating agencies attribute its competitive standing directly to its strong market position as "one of the three major U.S. pharmaceutical distributors" — this is the hardest layer.
  • Switching cost (strong): once hospitals, chain/independent pharmacies, specialty customers, and manufacturers embed procurement, inventory, replenishment, logistics, compliance, specialty support, reimbursement, and data processes into a national platform, switching involves systems, contracts, compliance, cash-cycle timing, and supply continuity — far from "reordering." The company itself warns that changes in key customers and payment terms can materially affect cash flow, which in turn shows the customer relationships themselves are core assets.
  • License and compliance (strong): pharmaceutical distribution is bound by the FDA, state/federal distribution standards, track-and-trace, and warehousing and transport requirements; even a well-funded new entrant would find it hard to replicate the national network, compliance system, customer certification, and manufacturer trust in a short time — the report judges that replicating its U.S. core platform would need "many years, several-billion-dollar-scale capital, and long-term certification," not a business a VC can replicate by burning cash for ten quarters.
  • Operating data (moderately strong): the larger the platform, the more order and drug-flow data it has, and the stronger its service capability, forming a kind of "operating-data flywheel"; but the report also honestly notes that this does not form the powerful network effects of an internet platform.

  Will it widen or narrow over the next three to five years? The report's judgment (which I agree with) is: the core distribution moat is broadly stable, the service-type moat is widening, but the pure-distribution profit pool itself is not fat. The case for widening is that the company is using OneOncology, RCA, and PharmaLex to extend from moving drugs toward embedding in specialty care, which raises gross margin and stickiness; the risk of narrowing/pressure comes from technology substitution — the FTC also notes that large pharmacies, mail-order pharmacies, and specialty pharmacies sometimes buy directly from manufacturers, and supply-chain direct connections, manufacturer direct shipping, and improved PBM/large-pharmacy self-operation would gradually squeeze intermediary value. Combined with the decline in a large mail-order customer's volumes and the loss of oncology and grocery customers already seen in FY2026 Q2, this shows the moat is wide but not "un-erodible."

  A key honest addition: a wide moat ≠ thick profit. This business has a very hard moat, but what it protects is a razor-thin-margin track — FY2025 net margin attributable to Cencora was under 0.5%, on which basis the report holds industry attractiveness at 3/5 and gives the moat 4/5. In other words, the moat ensures it "executes irreplaceably and steadily collects thin profit," rather than letting it use the moat to hike prices for windfall profit like consumer goods. In FY2026 Q2 the company noted that GLP-1 drags down gross margin while OneOncology lifts it — a portrayal of "relying on mix optimization rather than blunt price increases" (see Q2 FY2026 results).

  Conclusion: this is a wide, stable infrastructure moat that is extremely hard to replicate, with a low probability of disruption within three to five years; but it is the "defend thin profit, thicken slowly" type, not the "self-accelerating, ever-deepening" type. By Baillie Gifford's yardstick, Cencora stands very firm on the moat, yet this is also the very root of its "ample stability but limited upside imagination."

  Jun 11, 2026
• QIf the core business is disrupted, does it have the DNA to reinvent itself? How does it treat mistakes and bad news?5/10

  A

  Cencora's "self-reinvention DNA" is gradual and institutionalized, not the founder-style disruptive rebirth: it is good at continuously upgrading along the same supply-chain axis (from pure distribution → specialty services → compliance/care platforms), but it is hard to imagine it conjuring a brand-new business out of thin air if core distribution were fundamentally disrupted. Toward mistakes and bad news, its attitude leans honest and toward "owning it financially," but it is more an after-the-fact acknowledgment via impairment and disclosure than the founder's painful, fast error-correcting culture.

  First, the implicit premise of "self-reinvention" — whether it can be reborn when the core business is disrupted. Cencora's disruption risk is not "being killed by an app" but the gradual squeezing of the middle link by supply-chain direct connections, manufacturer direct shipping, and PBM/large-pharmacy self-operation (the FTC also notes that large/mail-order/specialty pharmacies sometimes buy directly from manufacturers). Facing this chronic erosion, the company's demonstrated response is to "embed deeper into the value chain": upgrading itself from moving drugs to a service platform embedded in oncology (OneOncology), ophthalmology (EyeSouth), and compliance (RCA, PharmaLex), using higher margins and stronger stickiness to hedge the squeezed value of pure distribution. This shows it has the DNA to "self-upgrade along the main channel" — but note, this is extension, not rebirth: all its remaking still revolves around the single axis of the "pharmaceutical supply chain," and once that axis is structurally breached, there is no evidence the company could switch to survive in an entirely different track like a top-tier growth stock. So its reinvention DNA is "present, but of the defend-and-upgrade type, not the phoenix-rebirth type."

  Next, a real "crisis-resilience" evidence point: in 2020 the company recognized a $6.6B legal accrual over opioid-related historical matters and posted a $3.409B net loss attributable to Cencora that year, but even under such a hammer operating cash flow stayed positive (about $2.2B). This shows its underlying business can withstand extreme shocks and does not easily collapse — a kind of "shock-absorbing" resilience, but that is different from "reinvention after disruption": the former is stability, the latter is change.

  Most crucial is how it treats mistakes and bad news, precisely the cultural signal Baillie Gifford values most, and I give a calm two-sided assessment:

  Positive: it tends to put bad news on the table and own it financially. In FY2026 Q2 it proactively disclosed the volume decline at a large mail-order customer and the 2025 loss of an oncology customer and a grocery customer, without hiding it; in FY2025 it took an $837M asset impairment — an impairment is essentially an admission that "some past capital allocation returned less than expected," and the company did not dodge it. On governance, long-term incentives tied to adjusted EPS, adjusted ROIC, and relative TSR (per the 2026 proxy materials) mean the board evaluates management on per-share value and capital efficiency rather than sheer scale — an error-correcting mechanism that "does not reward empire-building."

  Reservation: this "owning up" is more an after-the-fact accounting acknowledgment and disclosure compliance than the founder-style "cut losses fast, change painfully at the cultural level." The report explicitly notes this is a mature professional-manager system, not founder-controlled governance; the owner mindset shows in metric design and buyback discipline rather than large management equity ownership; management is "rational, institutionalized, and long-term-leaning, but not yet the scarce kind of brilliant capital-allocation genius." What warrants more vigilance is that the rising pace of M&A can itself create new mistakes — if OneOncology, RCA, the ophthalmology assets, and PharmaLex fail to generate higher long-term returns, the company will become "more complex, more leveraged, and more dependent on non-GAAP explanations," and the next impairment will be yet another after-the-fact acknowledgment of today's optimism.

  Conclusion: Cencora has the DNA to "continuously self-upgrade along the main channel" and the resilience to "not collapse under extreme shocks," and it is fairly honest about mistakes with institutionalized error-correcting metrics; but it lacks founder-style disruptive-rebirth capability, and its error-correction leans toward after-the-fact accounting acknowledgment rather than cultural pain. On Baillie Gifford's yardstick, this item is a "qualified mature company," not "a great company that fights ever harder amid bad news and dares to overturn itself" — consistent with the report's "Watch" rating, its 3.5/5 on capital allocation, and its emphasis on "needing continued proof that M&A is creating per-share value."

  Jun 11, 2026
• QDoes management (especially the founders) have a long-term vision, with interests deeply tied to the company? Are they willing to sacrifice current profit for five to ten years out?4/10

  A

  Management is a mature professional-manager system that is "institutionalized, long-term-leaning, and correctly incentive-designed," but not the founder-style deep interest binding — there is no founder/controlling shareholder, management's own equity holding is limited, and the willingness to "sacrifice current profit for five to ten years out" is constrained mainly by performance metrics and buyback discipline rather than driven by large personal equity. This is Cencora's inherent weakness on this Baillie Gifford dimension.

  First, the real structure of interest binding. Cencora is professional-manager governance, not founder-controlled governance (the report's clear judgment), and the current CEO is Robert P. Mauch. The binding is through incentive design rather than a bet of personal net worth: per the 2026 proxy materials, long-term incentives are heavily tied to adjusted EPS, adjusted ROIC, and relative TSR; the company disclosed a compound adjusted EPS growth rate of 13.21% and an average annual adjusted ROIC of 20.63% for the 2023–2025 performance period. This metric set points the right way — it evaluates "per-share value" and "capital efficiency" rather than "making revenue and scale bigger," which can institutionally suppress management's impulse to grow for growth's sake. But the report also honestly points out: the owner mindset "shows up more in metric design and buyback discipline than in large management equity ownership," and management overall is "rational, institutionalized, and long-term-leaning, but not yet the scarce kind of brilliant capital-allocation genius." This is precisely the most obvious gap versus Baillie Gifford's preferred "founder who stakes the vast majority of their net worth on the company and lives or dies with minority shareholders" — the report itself also admits in its open questions that the "precise management/director ownership percentages" were not fully extracted this round, but the qualitative conclusion is clear: the binding is "professional" enough, not "founder" enough.

  Next, the evidence on "whether it is willing to sacrifice current profit for the long term," laid out on both sides:

  Evidence of willingness to invest for the long term — the company channels large amounts of cash into specialty-platform acquisitions that take time to pay off: OneOncology (cash consideration about $5.0B), RCA, EyeSouth, and PharmaLex, bringing near-term amortization, impairment, and a rising interest burden (net interest expense rose markedly in the first half of FY2026 due to related financing) in exchange for higher future gross margin and stronger stickiness. This trade-off of "bearing short-term financial drag first, betting on long-term structural upgrade" is directionally aligned with long-termism.

  Evidence of disciplining the present and rewarding shareholders — management has clear buyback discipline: diluted share count fell from 220.3 million in 2018 to 195.2 million in 2025, about an 11.4% reduction; on the FY2026 Q2 call the CEO said it was already advancing debt repayment and preparing to resume opportunistic buybacks, and expected to repurchase $1 billion of stock by the end of 2026, while raising FY2026 adjusted EPS guidance to $17.65–17.90. This shows it is willing to invest in long-term M&A while also observing short-term capital discipline — it is "balanced and steady," rather than Baillie Gifford's preferred "dares to sacrifice the present heavily for ten years out, even at the cost of ugly financials."

  Points to keep guarding: the rising pace of M&A plus rising leverage (OneOncology's added notes and term loan) means the "room for error" shrinks. The report therefore holds management and capital allocation at 3.5/5 and lands its conclusion at "broadly trustworthy and reasonably rational, but needs continued proof that acquisitions extending the service platform are truly creating per-share value, not chasing a more complex, larger company." In other words, this management's "long-termism" still needs M&A delivery as its backing and cannot be trusted unconditionally.

  Conclusion: this is a trustworthy mature management team with correct incentive design, buyback discipline, and willingness to invest in long-term structural upgrade; but it lacks founder-style deep equity binding, and its long-term vision is driven by institutions rather than personal net worth. On Baillie Gifford's yardstick, on this dimension Cencora is an "above-average professional manager" rather than "a founder deeply bound to the company's fate" — this is a structural weakness for it as a growth-investment target and the reason the report repeatedly asks to "track M&A delivery."

  Jun 11, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and not reliant on harming society and regulation?6/10

  A

  If Cencora disappeared tomorrow, its customers (hospitals, pharmacies, specialty clinics, manufacturers) would miss it dearly — it is one of the critical pieces of infrastructure determining whether U.S. drugs reach patients on time, in compliance, and without stock-outs, and it is extremely hard to replace in the near term; moreover, its growth model is essentially "making drugs flow more efficiently and safely," a net social benefit that does not rely on harming the public or exploiting regulatory loopholes, giving it strong sustainability. Cencora answers this item quite beautifully — it is one of the dimensions that best withstands Baillie Gifford's scrutiny.

  First, indispensability. Cencora is one of the "three national pharmaceutical wholesalers" in the U.S. (the FTC makes this structure clear in its pharmaceutical distribution competition materials), and prescription drugs typically reach patients through the chain manufacturer → wholesaler → pharmacy/PBM. If it disappeared, what is affected is not "one fewer supplier" but the continuity of the entire distribution chain: once hospitals and pharmacies have embedded its procurement, inventory, replenishment, logistics, compliance, specialty support, reimbursement, and data processes, switching is by no means reordering — it involves systems, contracts, compliance certification, cash-cycle timing, and supply continuity. The company itself warns that "changes in the payment terms of key customers or suppliers can materially affect operating cash flow," which in turn shows both sides are deeply interlocked and hard to replace abruptly. A powerful stability data point: even in the extreme year of 2020, hammered by opioid litigation and posting a $3.409B net loss attributable to Cencora, the company's operating cash flow stayed positive (about $2.2B) and drugs kept flowing — showing it bears a "cannot-stop" social function.

  But an honest discount must be applied to the "degree of missing it": its indispensability is "system-level," not "Cencora alone is irreplaceable." Because it is a three-oligopoly structure, a single large customer could, over a long enough time and at a large enough cost, in theory migrate its business to McKesson or Cardinal, or shift partly to manufacturer direct shipping/self-operation (the FTC also notes that large, mail-order, and specialty pharmacies sometimes buy directly from manufacturers). In FY2026 Q2 the company disclosed the volume decline at a large mail-order customer and the 2025 loss of an oncology customer and a grocery customer — proving that customers "can switch, it is just expensive and slow to do so." So the precise statement is: customers would dearly miss efficient distribution, and would dearly miss the migration cost, but would not miss it to the point of "it must be Cencora." Its moat is switching friction, not monopolistic lock-in.

  Next, the other layer Baillie Gifford requires — whether growth is sustainable and does not harm society and regulation. On this side Cencora is cleaner than most high-growth stocks: its core value is delivering drugs more safely, more compliantly, and at lower cost from factory to patient; the FDA, state/federal distribution standards, and track-and-trace are themselves regimes it must satisfy and help implement, making it an enforcer of regulation rather than an evader. Its growth sources are real medical demand (innovative drugs, oncology, specialty, GLP-1) and service-mix upgrade, not misleading consumers or regulatory arbitrage.

  But history also sounds a warning that must be honestly counted: the 2020 opioid-related matter recognized a $6.6B legal accrual, showing that once a distributor's balance between "drug access" and "abuse prevention" tips, it bears enormous social and legal costs. This is both a risk tail and, in reverse, proof of its social importance — regulators watch it closely precisely because it holds the throat of drug distribution. The report therefore lists regulatory and legal risk as one of the three big uncertainties. Looking ahead, drug-pricing policy, track-and-trace, antitrust, and Medicare/subsidy changes could all shock its profit structure or cash-payment cadence, but these are risks of "being tightened within the compliance framework," not risks that "the business model itself is anti-social" — the two are entirely different in nature.

  Conclusion: indispensability is strong (system-level, resting on switching friction rather than monopoly) and social/regulatory sustainability is strong (enforcing regulation rather than evading it, with growth from real medical demand), with only the opioid history warning that a distributor is not zero-tail-risk. On Baillie Gifford's yardstick, this is Cencora's hardest item — it really is a business that "would be truly missed if it disappeared and earns socially sanctioned money"; this also underpins the report's bull core of "real demand, strong industry position, no reliance on trendy themes, and a high probability of continuing to earn money over the long run."

  Jun 11, 2026
• QWhat are the unit economics of this business (gross margin, incremental returns)? Do they get better or worse as scale grows? Where does the money it earns go?4/10

  A

  The unit economics are a classic distribution model of "razor-thin gross margin, amplified by astronomical turnover, yet with fairly high incremental capital returns": gross margin and net margin look ugly in absolute terms, but because invested capital turns over extremely fast, adjusted ROIC reaches about 20%; as scale grows, unit economics improve mildly (mix upgrade is lifting gross margin), and the money it earns goes mainly into acquiring specialty platforms, buying back stock, and repaying debt. This is a business with "ugly financials but decent capital efficiency," yet the thickness of its unit economics cannot support the windfall-type growth Baillie Gifford prefers.

  First, lay out the truth of the unit economics — absolute margins are razor-thin. FY2025 revenue was about $321.3B, net income attributable to Cencora was only $1.554B, and net margin attributable to Cencora was under 0.5%; gross profit was $11.48B (gross margin about 3.6%). This means for every $100 of drugs distributed, the company grosses about $3.6 and nets less than $0.50. So the unit economics of this business must never be viewed with a consumer-goods margin mindset — the report repeatedly stresses that what truly deserves attention is not the absolute net margin but gross-margin improvement, expense control, capital turnover, and per-share value accumulation.

  But a thin gross margin does not equal a bad business; the key lies in incremental returns and turnover. The company disclosed an average annual adjusted ROIC as high as 20.63% for 2023–2025 and compound adjusted EPS growth of 13.21% — showing that although each order's profit is razor-thin, the proprietary invested capital it ties up is likewise very small (the distribution business finances itself via supplier payment terms and turns over asset-light), and the result is "thin profit × high turnover = a solid return on capital." One direct piece of evidence: FY2025 operating cash flow was about $3.9B, and one important source was a $3.7B increase in accounts payable — that is, suppliers are financing its working capital, the smartest link in a distribution leader's unit economics. Capex is also extremely light, at only $310–370M per year in FY2018–2020, nearly negligible relative to hundred-billion-scale revenue, so the incremental business barely relies on heavy-asset investment.

  Do unit economics get better or worse as scale grows? Mildly better, but on the back of mix upgrade rather than sheer volume. Simply moving more boxes will not materially improve that 3.6% gross margin, and high-revenue, low-margin categories like GLP-1 even dilute the headline gross margin (the company said so explicitly in FY2026 Q2). What actually lifts unit economics is "extending toward high-margin specialty services": in FY2026 Q2 the company noted OneOncology lifted the U.S. business's gross margin and operating profit (see Q2 FY2026 results); FY2026 Q2 adjusted diluted EPS rose 7.5% year over year to $4.75, outpacing revenue's +3.8%, which also confirms that "profit grows faster than revenue and unit economics are improving." So the scale effect is real, but it comes from category/service-mix optimization plus procurement bargaining plus route density, not simply "bigger means more profitable."

  Where does the money it earns go? Three destinations, characterized one by one:

  • Buybacks (broadly positive): diluted share count fell from 220.3 million in 2018 to 195.2 million in 2025, about an 11.4% reduction; FY2026 plans to repurchase $1 billion by year-end. In a thin-margin business, shrinking the share count via buybacks is an effective lever to amplify per-share value.
  • Acquiring specialty platforms (needs watching): OneOncology (cash consideration about $5.0B), RCA, EyeSouth, PharmaLex — the direction is buying higher-margin incremental returns, but FY2025 already took an $837M asset impairment, signaling that acquisition returns do not all hit the mark, which is why the report demands "continued proof that M&A is creating per-share value."
  • Debt repayment (passive spending rising): OneOncology financing pushed up leverage, so net interest expense rose markedly in the first half of FY2026, and the company is using cash flow to advance debt repayment. This part is capital tied up in "paying for the expansion."

  One discount that must be applied on the unit economics — the "distributability" of cash flow carries a question mark. The report repeatedly stresses that operating cash flow varies substantially with period-end working capital (receivables, inventory, payables), and that changes in the payment terms of key customers or suppliers materially affect CFO. Of that $3.9B FY2025 CFO, $3.7B came from a rise in accounts payable; good years release cash and bad years give it back — so a single year's pretty CFO cannot be treated as "money the owner can take home today." On this basis the report estimates normalized Owner Earnings at about $2.7–3.1B (midpoint about $2.9B), clearly below the $3.9B CFO and above the $1.55B of GAAP net income. This is precisely the most subtle part of this business's unit economics: the incremental return rate is not low, but the "real distributable cash that actually lands in your pocket" must be viewed at a discount.

  Conclusion: the unit economics are a distribution-leader model of "thin gross margin + high turnover + high ROIC + light capex + but cash-flow distributability needs a discount"; growth in scale improves them mildly via mix upgrade rather than sheer volume; the money earned goes mainly to buybacks, acquiring specialty platforms, and debt repayment. The capital efficiency is worthy of a "good business," but the thickness of the unit economics (net margin <0.5%) destines it for steady compounding rather than the high-margin windfall growth Baillie Gifford prefers — fully consistent with the report holding industry attractiveness at 3/5 while endorsing the ROIC and buyback discipline.

  Jun 11, 2026
• QFor it to rise five-fold in ten years, which conditions must hold simultaneously? Are these conditions realistic? What expectations does today's stock price imply?2/10

  A

  Five-fold in ten years is a very high bar for Cencora, requiring several conditions to hold at once, most of which are not easy: its realistic compounding path is more likely the "two-to-three-fold in ten years" level, not five-fold. And today's roughly $282 stock price already implies not "cheap" but "quality plus steady growth fully priced in" — the margin of safety is not meaningful, and the room left for upside is compressed.

  First, the hard arithmetic of five-fold in ten years (the implicit premise Baillie Gifford requires). Five-fold in ten years ≈ about 17.5% annualized total shareholder return. For a thin-margin distributor with FY2025 net margin attributable to Cencora under 0.5% and core revenue running only in the low single digits (FY2026 Q2 U.S. business +2.9%, total revenue +3.8%), to muster 17.5%/year requires the following conditions to hold "simultaneously":

  • Profit growth far outpacing revenue: using specialty-service mix upgrade to keep lifting gross margin and operating margin, so that per-share earnings run in the mid-to-high double digits over the long run (reference the 2023–2025 compound adjusted EPS growth of 13.21%, but it must be sustained or even accelerated over a ten-year horizon);
  • Buybacks continuing to amplify per-share value: on top of the 11.4% (2018→2025 share-count reduction), keep aggressively shrinking the share count without being offset by acquisition-related issuance;
  • M&A all delivering, no more large impairments: OneOncology, RCA, ophthalmology, and PharmaLex truly converting into high returns, rather than taking an $837M impairment as in FY2025;
  • Leverage digested smoothly: the interest burden pushed up by OneOncology financing (net interest expense rose markedly in the first half of FY2026) offset by cash flow, with the rating holding investment grade;
  • Valuation not contracting: the market's willingness to grant it a multiple at least does not slip — and this is precisely the problem, because today's multiple is already not low.

  Each of these five conditions on its own is not outlandish, but the joint probability of "all holding simultaneously over ten years with none faltering" is not high; as soon as M&A delivery is discounted, or working capital cannot normalize, or valuation reverts, the compounding slides from "five-fold" toward "two-to-three-fold." This is also why the report sets expected annualized return at "8%–10% conservative, 11%–13% base, and 14%+ optimistic at the ideal buy price, to be marked down across the board if bought at the current market price" — even in the optimistic scenario the report itself gives 14%+, not 17.5%, which already shows that five-fold sits near the ceiling of the optimistic scenario in its framework, not the base case.

  Next, what expectations does today's price imply. The current price is about $281–283/share, market cap about $54–55B, with a 52-week range of $244.82–$377.54 (it spiked to 377 within the year before pulling back). Valuation multiples: on the FY2026 adjusted EPS guidance $17.65–17.90 midpoint of about 17.78, the forward P/E is about 15.8x; on a TTM basis, stockanalysis shows a trailing P/E of about 21.5x. Cross-sectionally, GuruFocus shows its forward P/E at about 18.99, more than 30% above the pharmaceutical-distribution industry median of about 14; price-to-FCF is about 22.3x, above McKesson's roughly 18.2x and Cardinal's roughly 11.3x (see Financhill industry comparison).

  These multiples show the market's implied expectation is: pricing Cencora's "stability plus specialty story" quite fully — it already enjoys a higher-end quality premium within the three oligopolists, with the market assuming it can grow steadily, integrate M&A smoothly, and keep cash flow high-quality. Against the report's intrinsic-value framework (fair-value range $250–300, optimistic $320–350, ideal buy $210–245), roughly $282 falls in the "upper-middle of the fair-value range," clearly above the $210–245 range at which the report is willing to buy actively. The report therefore judges directly that "the margin of safety is not meaningful … the current market price looks closer to the upper end of fair value."

  Two sides to give honestly: on one hand, $282 has not yet reached the report's "clearly overvalued range (above 320–350)" and is below the year's high of 377, so it is not a crazy bubble; on the other, it is by no means cheap enough to leave room for error for "five-fold in ten years" — the innate issues of thin margins, M&A, and working-capital volatility are not compensated by a sufficient discount at this price level.

  Conclusion: five-fold in ten years requires profit growth, buybacks, M&A delivery, deleveraging, and non-contracting valuation to all succeed at once, with a low joint probability; more realistic is steady compounding at the two-to-three-fold-in-ten-years level. And today's roughly $282 price implies "quality and steady growth fully priced in," with no meaningful margin of safety. This is precisely the core logic of the report assigning "Watch" rather than "Buy" and holding the fair buy price at 210–245 — a good company, but the current price is not a worthwhile entry point for "five-fold in ten years."

  Jun 11, 2026
• QWhy hasn't the market realized all this yet? Is it that it cannot understand it, looks down on it, or cannot see far enough? What would become the "narrative turning point"?3/10

  A

  This question must be answered honestly in reverse for Cencora: the market in fact "both understands it and respects it" — it is not a neglected, mispriced, dust-covered stock but a quality leader that is fully understood and no longer cheap on valuation. So there is no "perception gap the market has not yet realized" to arbitrage here; the real question is not "why is it cheap" but "why is it not cheap." The narrative turning point is therefore two-directional: upward hinges on the specialty platform delivering, downward on M&A/working-capital/policy surprises.

  First, dispel the premise that "the market cannot understand it / looks down on it / cannot see far enough." Baillie Gifford's question presupposes an undervaluation perception gap for the target, but Cencora's facts point the opposite way:

  • Not "cannot understand it": this business has clear logic and ample institutional coverage. It is one of the U.S. three oligopolists (the FTC materials are explicit), credit-rating agencies attribute its competitive standing directly to its "three major pharmaceutical distributors" position, and the report itself scores business understandability at 4/5.
  • Not "looks down on it": valuation is precisely on the high side. On the FY2026 adjusted EPS guidance $17.65–17.90 midpoint, the current roughly $282/share implies a forward P/E of about 15.8x; on GuruFocus's measure the forward P/E is about 18.99, more than 30% above the industry median of about 14, and price-to-FCF of about 22.3x is also above McKesson's roughly 18.2x and Cardinal's roughly 11.3x (see industry comparison). The market clearly "respects it," even granting a full quality premium.
  • No "cannot see far enough" dividend to speak of: the market has already priced in the "stability plus specialty story" to a considerable degree, and the stock spiked to its 52-week high of $377.54 within the year, showing the long-term imagination was reflected long ago.

  So the honest conclusion is: Cencora has no "undervaluation the market has not yet realized"; it is closer to a quality asset that is "correctly priced, even priced on the full side." This is fully consistent with the report's judgment that "I do not see a clear enough discount, and the margin of safety is not meaningful" — forcing a search for a nonexistent perception gap and going bullish on that basis is, ironically, the easiest mistake to make on this question.

  If one must say what the market may "underweight," only a reverse risk-perception gap is worth mentioning: the market may underestimate the "water" in this business's "cash-flow distributability" — of that $3.9B FY2025 operating cash flow, $3.7B came from a rise in accounts payable, so the report marks normalized Owner Earnings down to about $2.7–3.1B, clearly below CFO. If the market prices it on "pretty CFO," that is overvaluation rather than undervaluation. This is also why the report repeatedly cautions "do not treat a single year's CFO as owner's profit."

  What would become the narrative turning point (the question Baillie Gifford requires)? Both directions, laid out clearly:

  The upward turning point (letting the valuation premium be validated or even expand) — the specialty platform truly delivering: OneOncology and others continuously lifting the U.S. business's gross margin and operating margin for several consecutive quarters, with no more large impairments; the interest burden receding as debt falls and the rating holding investment grade; Owner Earnings per share climbing step by step. If these happen, the market will gradually re-rate it from a "distributor valuation" to a "healthcare-services-platform valuation" — its only path to breaking the "ample stability, limited upside" label.

  The downward turning point (letting the current premium collapse) — the report lists it clearly: sustained loss of U.S. core distribution share (not a single quarter but multiple large customers stacking up, with the FY2026 Q2 signs of a large mail-order customer's volume decline and the loss of oncology and grocery customers already showing); working capital that can no longer normalize, with CFO persistently below normalized net income plus depreciation and amortization; a stall in the M&A gross-margin lift and a rating outlook turning negative; or a major policy/litigation shock from drug-pricing policy, track-and-trace, antitrust, and the like again amplifying the income statement or cash flow. If any of these occurs, the market will quickly switch from "quality premium" to a "thin-margin distribution plus high leverage" discount narrative — the report estimates a mid-term 30%–45% capital drawdown "would not be an exaggeration."

  Conclusion: Cencora's true picture is not "undervalued, awaiting the market's awakening" but "fully understood, valuation on the full side, margin of safety not meaningful" — so the honest answer to this question is that the market both understands it and respects it, with no arbitrageable perception gap. The narrative turning point is two-directional: upward via the specialty platform delivering consecutively and being re-rated as a service platform, downward via M&A/working-capital/policy surprises. This precisely supports the report's final landing point of "a good company, but the current price better fits patient waiting than active accumulation — respect business quality first, then respect price discipline."

  Jun 11, 2026